Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lipoic acid choline ester - Novartis

Drug Profile

Lipoic acid choline ester - Novartis

Alternative Names: EV-06; Lipoic acid choline ester 1.5%; Lipoic acid choline ester chloride; Thioctic acid choline ester; UNR 844; UNR844-Cl

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Encore Vision
  • Developer Novartis
  • Class Carboxylic acids; Coenzymes; Esters; Eye disorder therapies; Fatty acids; Hepatoprotectants; Quaternary ammonium compounds; Sulfhydryl compounds; Thiophenes
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 09 Apr 2019 Novartis plans to launch Lipoic acid choline ester in 2019
  • 18 Mar 2019 Chemical structure information added
  • 18 Jan 2019 Novartis plans a phase II trial for Presbyopia in April 2019 (NCT03809611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top